Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Establishment Labs Holdings ( (ESTA) ) has issued an update.
On September 29, 2025, Establishment Labs Holdings Inc. amended its Credit Agreement with Oaktree Fund Administration, allowing for the immediate availability of Tranche D Term Loans and increasing the required minimum liquidity from $25 million to $30 million. The company fully borrowed $25 million under the new terms, which could enhance its financial flexibility and support its operational strategies.
The most recent analyst rating on (ESTA) stock is a Hold with a $42.00 price target. To see the full list of analyst forecasts on Establishment Labs Holdings stock, see the ESTA Stock Forecast page.
Spark’s Take on ESTA Stock
According to Spark, TipRanks’ AI Analyst, ESTA is a Neutral.
Establishment Labs Holdings’ overall score is driven by strong revenue growth and positive guidance from the earnings call. However, financial performance concerns, including high debt and negative cash flows, weigh heavily on the score. Technical indicators provide some support, but valuation remains a challenge due to ongoing losses.
To see Spark’s full report on ESTA stock, click here.
More about Establishment Labs Holdings
Establishment Labs Holdings Inc. operates in the medical technology industry, focusing primarily on the development and manufacturing of advanced silicone breast implants and other medical devices. The company is known for its innovative products aimed at improving patient outcomes and safety in the aesthetic and reconstructive surgery markets.
Average Trading Volume: 350,858
Technical Sentiment Signal: Hold
Current Market Cap: $1.22B
See more insights into ESTA stock on TipRanks’ Stock Analysis page.